Cepheid (CPHD) 59.62 $CPHD
Cepheid Receives FDA Clearance for Expanded Claims on Tuberculosis Test
PR Newswire - Fri Feb 13, 6:00AM CST
Cepheid (Nasdaq: CPHD) today announced it has received clearance from the U.S. Food & Drug Administration (FDA) for expanded claims on its Xpert® MTB/RIF test. Xpert MTB/RIF detects Mycobacterium tuberculosis complex (MTB-complex) DNA and in positive specimens, provides simultaneous identification of rifampin-resistance associated mutations of the rpoB gene. The expanded product claim enables clinicians to use either one or two negative Xpert MTB/RIF test results, in conjunction with other clinical and laboratory data, to remove patients from airborne infection isolation (AII), commonly referred to as respiratory isolation. The test runs on the Cepheid GeneXpert® System, the world's leading molecular diagnostic platform with over 8,000 systems deployed globally in both developed and emerging market countries.
CPHD: 59.62 (+0.72)
Cepheid Strong on Q4, Global Expansion; Currency Woes Stay - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 1:09PM CST
Cepheid (CPHD) reported adjusted breakeven earnings per share in the quarter, which compared favorably with the Zacks Consensus Estimate of a loss of 14 cents.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), CPHD: 59.62 (+0.72), LMNX: 15.45 (+0.02)
Healthcare stock screen of the month: Accelerating after-tax margins
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 11:21AM CST
MNK: 115.01 (+2.51), BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), BCR: 175.38 (+0.50), EVHC: 36.20 (-0.09), TMO: 127.61 (+0.78), CAH: 86.08 (+0.04), UTHR: 151.11 (+3.59), ILMN: 198.54 (+1.81), ACOR: 36.14 (-0.51), LCI: 57.78 (-0.91), JAZZ: 169.69 (+6.89), SHPG: 239.82 (+6.11), CPHD: 59.62 (+0.72), SYK: 94.51 (+1.14)
Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/b4g8s4/molecular) has announced the addition of the "Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics" report to their offering. Topics covered in this study include: 1) the existing and emerging technologies in the field, 2) the U.S. and global market size for molecular diagnostic products and 3) the profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. This publications report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics-along with the development of microarray devices to measure analytes in the blood-has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - Siemens AG - SIRS-Lab - TrovaGene - Veredus Laboratories - Veridex, LLC (Janssen Diagnostics, LLC) For more information visit http://www.researchandmarkets.com/research/b4g8s4/molecular
GNMK: 13.51 (+0.21), ABT: 46.09 (+0.87), MYGN: 34.03 (+0.40), AGMX: (), CPHD: 59.62 (+0.72), ILMN: 198.54 (+1.81), QGEN: 23.68 (-0.06), LMNX: 15.45 (+0.02)
Global Bio-detection (1st, 2nd & 3rd Generation) Market 2014-2018 with Agilent Technologies, Cepheid, Roche Diagnostics & Smiths Group Dominating
M2 - Sat Jan 31, 1:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/n5mnwh/global) has announced the addition of the "Global Bio-detection Market 2014-2018" report to their offering. The Global Bio-detection market to grow at a CAGR of 14.19% over the period 2013-2018. Bio-detection has emerged as a solution to the public and governments. With an increase in bio-terrorism, the occurrence of illness and deaths is very frequent. This event is caused by the airborne chemicals or pathogens that are released by a terrorist or a group of people or even by an individual for a motive. These pathogens can be detected by a system called bio-detection, which signals the entry or the existence of a virus. The increasing attacks have brought a major concern to the public as well as governments. Attacks such as the 2001 Anthrax scare, the 2003 severe acute respiratory syndrome (SARS), the 2004 Ricin letters, the 2009 H1N1, and the 2014 Ebola outbreaks have driven governments to increase their bio-surveillance budgets. To calculate the market size, the report considers the revenue generated from the sales, services, and upgrades of the bio-detection system in the Government sector. The increased need for bio-security is one of the major trends witnessed in the market. The increase in bio-terrorist attacks has increased the need for bio-security systems that secure people from pathogen attacks and reduce the risk of disease transmission to others. According to the report, the need for an early detection system for bio-terrorist attacks is one of the major drivers in the market. The existing bio-detection systems take a long time to detect and confirm the presence of a virus, and this can be fatal. Therefore, research is being conducted to introduce fast detection systems. Further, the report states that difficulty in detecting the presence of pathogens is one of the major challenges in the market. The minute presence of pathogens in air, water, and food makes it difficult to detect, and hence the detectors show a negative result. The bio-detection systems considered in this report are listed below: - 1st generation bio-detection systems - 2nd generation bio-detection systems - 3rd generation bio-detection systems Key Vendors - Agilent Technologies - Cepheid - Roche Diagnostics - Smiths Group Other Prominent Vendors - 20/20 GeneSystems - 3M Microbiology - Advnt Biotechnologies - Alexeter Technologies - ANP Technologies - BAS - Biological Alarm Systems - BD Biosciences Immunocytometry Systems - Bertin Technologies - Biodefense - BioDETECT - BioSentinel Pharmaceuticals - BioTraces - BioVeris - Commonwealth Biotechnologies - Dycor Technologies - Environics - Evogen - General Dynamics Canada - GenPrime - Groton Biosystems - Haztech Systems - JMAR Technologies - New Horizons Diagnostics - Proengin - Response Biomedical - Tetracore For more information visit http://www.researchandmarkets.com/research/n5mnwh/global
GD: 137.61 (-0.54), A: 40.15 (+0.13), CPHD: 59.62 (+0.72)
Research and Markets: Global Bio-detection (1st, 2nd & 3rd Generation) Market 2014-2018 with Agilent Technologies, Cepheid, Roche Diagnostics & Smiths Group Dominating
Business Wire - Fri Jan 30, 1:22PM CST
Research and Markets (http://www.researchandmarkets.com/research/djxzmx/global) has announced the addition of the "Global Bio-detection Market 2014-2018" report to their offering.
A: 40.15 (+0.13), CPHD: 59.62 (+0.72)
Cepheid Posts Breakeven Earnings; System Placements High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 12:40PM CST
Cepheid (CPHD) reported 773 commercial placements during 2014, reflecting a strong North American performance, and 544 international placements, which far exceeded Cepheid's previous record of 383 international placements in 2013.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), EW: 134.23 (+1.89), CPHD: 59.62 (+0.72)
Cepheid's (CPHD) CEO John Bishop on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Jan 29, 10:02PM CST
CPHD: 59.62 (+0.72)
Cepheid reports 4Q loss
Automated Insights - Thu Jan 29, 5:37PM CST
SUNNYVALE, Calif. (AP) _ Cepheid (CPHD) on Thursday reported a loss of $23.8 million in its fourth quarter.
CPHD: 59.62 (+0.72)
CEPHEID (CPHD) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Jan 29, 3:55PM CST
CPHD: 59.62 (+0.72)
CEPHEID beats by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 3:13PM CST
CPHD: 59.62 (+0.72)
Cepheid Reports Fourth Quarter And Full Year 2014 Results
PR Newswire - Thu Jan 29, 3:05PM CST
Cepheid (Nasdaq: CPHD) today reported revenue for the fourth quarter of 2014 of $131.5 million. Net loss was $23.8 million, or $(0.34) per share, which compares to revenue of $113.3 million and net loss of $10.3 million, or $(0.15) per share, in the fourth quarter of 2013. 2014 fourth quarter net loss included a legal contingency charge of $20 million, or $(0.28) per share.
CPHD: 59.62 (+0.72)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 4:35PM CST
VR: 42.10 (+0.07), BXP: 141.08 (-1.58), EPAY: 27.07 (+0.64), CPSI: 53.11 (+0.26), GOOG: 549.01 (+6.08), PKI: 46.30 (-0.10), JDSU: 13.26 (+0.23), TFSL: 14.47 (+0.18), MITK: 3.38 (-0.02), NFG: 65.15 (+0.60), EFII: 40.59 (+0.94), BCR: 175.38 (+0.50), MCHP: 50.71 (+0.73), PMCS: 9.24 (+0.07), PFPT: 55.97 (+0.38), ABAX: 60.93 (+0.65), CPHD: 59.62 (+0.72), PFG: 51.60 (+0.50), QLGC: 14.48 (+0.48), UIS: 23.37 (+0.27), TUES: 19.41 (-0.01), COHR: 64.95 (+0.25), PCCC: 23.66 (+0.05), CTCT: 42.48 (+0.72), BIIB: 391.66 (-0.45), SFG: 67.49 (+0.21), IXYS: 11.92 (-0.07), SYNA: 78.91 (+0.87), HLIT: 7.90 (+0.01), INVN: 16.08 (+0.09), CB: 102.06 (+0.43), N: 101.72 (+3.38), ELX: 6.57 (+0.22), GIMO: 21.45 (+1.10), SWI: 50.55 (+0.79), V: 269.63 (-1.28), ELY: 8.61 (-0.05), GDOT: 15.54 (+0.34), FICO: 82.00 (+1.50), HBI: 119.12 (+1.27), ISBC: 11.70 (+0.07), NATI: 31.20 (+0.31), NEU: 469.55 (+0.43), AMZN: 381.83 (+4.66), EMN: 75.67 (+0.56), ALGN: 56.90 (-0.34), BRCM: 45.69 (+0.23), HA: 18.72 (-0.31), DECK: 77.08 (+0.61), LEG: 44.90 (+0.17), MTW: 21.86 (+0.34), RVBD: 20.85 (-0.03), AVNW: 1.19 (+0.08), RHI: 61.42 (+0.04), NGVC: 30.28 (+0.45), CORT: 3.15 (+0.01)
Comparing America's 3 Largest Scientific And Technical Instruments Companies
Joseph Cafariello - at Seeking Alpha - Tue Jan 27, 6:52AM CST
FLIR: 33.01 (-0.23), TRMB: 26.86 (-0.40), CPHD: 59.62 (+0.72)
Microbiology Testing/Clinical Microbiology Market by Product, Clinical Application & by Industry - Global Forecast to 2019
M2 - Fri Jan 16, 8:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/cl7fxt/microbiology) has announced the addition of the "Microbiology Testing/Clinical Microbiology Market by Product, Clinical Application & by Industry - Global Forecast to 2019" report to their offering. The global clinical microbiology market is expected to reach $12,411.36 million in 2019 at a CAGR of 13.03% between 2014 and 2019. Clinical microbiology consists of a wide array of techniques for the detection of infectious diseases. The respiratory diseases segment accounted for the largest application segment of the clinical microbiology market in 2014. According to the WHO, in 2012, there were about 450,000 new cases of multidrug-resistant tuberculosis (MDR-TB), and extensively drug-resistant tuberculosis (XDR-TB) was identified in 92 countries. Furthermore, the outbreak of new diseases such as Ebola is expected to increase the disease burden and the demand for clinical microbiology products. The microbiology market is segmented on the basis of applications into clinical, energy, environment, food, manufacturing, and pharmaceuticals. The food application segment is expected to grow at the highest CAGR between 2014 and 2019 however, the pharmaceuticals application segment accounted for the largest share of the microbiology market in 2014. On the basis of products, the clinical microbiology market is segmented into consumables and instruments. The clinical microbiology consumables market is further bifurcated into kits and reagents, whereas the instruments market is sub segmented into automated microbiology instruments, laboratory instruments, and microbiology analyzers. The microbiology analyzers are further categorized into mass spectrometers, microscopes, and molecular diagnostics instruments. The laboratory instruments are further categorized into anaerobic gas systems, automated gram strainers, automated petri dish fillers, autoclave sterilizers, bacterial colony counters, incubators, microbial air samplers, and other laboratory instruments. Clinical microbiology finds applications in a large number of disease diagnosis. The clinical microbiology market on the basis of applications are segmented into bloodstream infections, gastrointestinal diseases, periodontal diseases, respiratory diseases, sexually transmitted diseases, urinary tract infections, and other diseases. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Microbiology Market, By Applications 8 Clinical Microbiology Market, By Product 9 Clinical Microbiology Market, By Applications 10 Clinical Microbiology Market, By Geography 11 Competitive Landscape 12 Company Profiles - Abbott Laboratories, Inc. - Alere, Inc. - Becton, Dickinson and Company - Bio-Rad Laboratories, Inc. - Biom?rieux SA - Bruker Corporation - Cepheid - Danaher Corporation - F. Hoffmann-LA Roche Ltd. - Hologic, Inc. - Siemens AG For more information visit http://www.researchandmarkets.com/research/cl...crobiology
ABT: 46.09 (+0.87), CPHD: 59.62 (+0.72), DHR: 86.81 (+0.21), ALR: 43.40 (-0.40), HOLX: 30.46 (+0.21)
Cepheid CFO bids adieu
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 8:16AM CST
CPHD: 59.62 (+0.72)
PTC Names Andrew Miller Chief Financial Officer
Business Wire - Mon Jan 05, 7:12AM CST
PTC (Nasdaq
TC) today announced the appointment of Andrew Miller as Executive Vice President and Chief Financial Officer (CFO), effective February 5, 2015. An accomplished finance executive, Miller has more than 30 years of experience in the high technology and medical technology industries.
CPHD: 59.62 (+0.72), PTC: 34.02 (+0.37), UNTD: 13.96 (-0.08)
Cepheid Announces CFO Change
PR Newswire - Mon Jan 05, 7:00AM CST
Cepheid (Nasdaq: CPHD) today announced that Andrew Miller, executive vice president and chief financial officer, will be leaving Cepheid to pursue an opportunity with PTC Inc., a Massachusetts-based technology solutions provider. Mr. Miller will continue to serve as Cepheid's CFO through February 3, 2015, directing Cepheid's financial operations and assisting with the upcoming transition.
CPHD: 59.62 (+0.72), PTC: 34.02 (+0.37)
Cepheid's (CPHD) Xpert HIV Test Wins CE-IVD Mark in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 1:40PM CST
Cepheid's (CPHD) HIV viral load test is the standard measurement which is used in the diagnosis of HIV positive patients and helps in administering antiretroviral therapy.
ETRM: 1.21 (+0.06), FLDM: 37.93 (-0.47), INGN: 33.53 (+2.32), CPHD: 59.62 (+0.72)
Cepheid and FIND Announce European Approval of Xpert HIV-1 Viral Load
PR Newswire - Mon Dec 29, 6:00AM CST
Cepheid (Nasdaq: CPHD) and the Foundation for Innovative New Diagnostics (FIND) today announced that Xpert® HIV-1 Viral Load, a quantitative test for measurement of the HIV-1 viral load in plasma, has a achieved CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices. The test runs on the Cepheid GeneXpert® System, the world's leading molecular diagnostic platform with over 7,500 systems deployed globally in both developed and emerging market countries.
CPHD: 59.62 (+0.72)
Cepheid Receives FDA Clearance for Expanded Claims on Tuberculosis Test
PR Newswire - Fri Feb 13, 6:00AM CST
Cepheid (Nasdaq: CPHD) today announced it has received clearance from the U.S. Food & Drug Administration (FDA) for expanded claims on its Xpert® MTB/RIF test. Xpert MTB/RIF detects Mycobacterium tuberculosis complex (MTB-complex) DNA and in positive specimens, provides simultaneous identification of rifampin-resistance associated mutations of the rpoB gene. The expanded product claim enables clinicians to use either one or two negative Xpert MTB/RIF test results, in conjunction with other clinical and laboratory data, to remove patients from airborne infection isolation (AII), commonly referred to as respiratory isolation. The test runs on the Cepheid GeneXpert® System, the world's leading molecular diagnostic platform with over 8,000 systems deployed globally in both developed and emerging market countries.
CPHD: 59.62 (+0.72)
Cepheid Strong on Q4, Global Expansion; Currency Woes Stay - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 1:09PM CST
Cepheid (CPHD) reported adjusted breakeven earnings per share in the quarter, which compared favorably with the Zacks Consensus Estimate of a loss of 14 cents.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), CPHD: 59.62 (+0.72), LMNX: 15.45 (+0.02)
Healthcare stock screen of the month: Accelerating after-tax margins
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 11:21AM CST
MNK: 115.01 (+2.51), BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), BCR: 175.38 (+0.50), EVHC: 36.20 (-0.09), TMO: 127.61 (+0.78), CAH: 86.08 (+0.04), UTHR: 151.11 (+3.59), ILMN: 198.54 (+1.81), ACOR: 36.14 (-0.51), LCI: 57.78 (-0.91), JAZZ: 169.69 (+6.89), SHPG: 239.82 (+6.11), CPHD: 59.62 (+0.72), SYK: 94.51 (+1.14)
Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/b4g8s4/molecular) has announced the addition of the "Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics" report to their offering. Topics covered in this study include: 1) the existing and emerging technologies in the field, 2) the U.S. and global market size for molecular diagnostic products and 3) the profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. This publications report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics-along with the development of microarray devices to measure analytes in the blood-has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - Siemens AG - SIRS-Lab - TrovaGene - Veredus Laboratories - Veridex, LLC (Janssen Diagnostics, LLC) For more information visit http://www.researchandmarkets.com/research/b4g8s4/molecular
GNMK: 13.51 (+0.21), ABT: 46.09 (+0.87), MYGN: 34.03 (+0.40), AGMX: (), CPHD: 59.62 (+0.72), ILMN: 198.54 (+1.81), QGEN: 23.68 (-0.06), LMNX: 15.45 (+0.02)
Global Bio-detection (1st, 2nd & 3rd Generation) Market 2014-2018 with Agilent Technologies, Cepheid, Roche Diagnostics & Smiths Group Dominating
M2 - Sat Jan 31, 1:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/n5mnwh/global) has announced the addition of the "Global Bio-detection Market 2014-2018" report to their offering. The Global Bio-detection market to grow at a CAGR of 14.19% over the period 2013-2018. Bio-detection has emerged as a solution to the public and governments. With an increase in bio-terrorism, the occurrence of illness and deaths is very frequent. This event is caused by the airborne chemicals or pathogens that are released by a terrorist or a group of people or even by an individual for a motive. These pathogens can be detected by a system called bio-detection, which signals the entry or the existence of a virus. The increasing attacks have brought a major concern to the public as well as governments. Attacks such as the 2001 Anthrax scare, the 2003 severe acute respiratory syndrome (SARS), the 2004 Ricin letters, the 2009 H1N1, and the 2014 Ebola outbreaks have driven governments to increase their bio-surveillance budgets. To calculate the market size, the report considers the revenue generated from the sales, services, and upgrades of the bio-detection system in the Government sector. The increased need for bio-security is one of the major trends witnessed in the market. The increase in bio-terrorist attacks has increased the need for bio-security systems that secure people from pathogen attacks and reduce the risk of disease transmission to others. According to the report, the need for an early detection system for bio-terrorist attacks is one of the major drivers in the market. The existing bio-detection systems take a long time to detect and confirm the presence of a virus, and this can be fatal. Therefore, research is being conducted to introduce fast detection systems. Further, the report states that difficulty in detecting the presence of pathogens is one of the major challenges in the market. The minute presence of pathogens in air, water, and food makes it difficult to detect, and hence the detectors show a negative result. The bio-detection systems considered in this report are listed below: - 1st generation bio-detection systems - 2nd generation bio-detection systems - 3rd generation bio-detection systems Key Vendors - Agilent Technologies - Cepheid - Roche Diagnostics - Smiths Group Other Prominent Vendors - 20/20 GeneSystems - 3M Microbiology - Advnt Biotechnologies - Alexeter Technologies - ANP Technologies - BAS - Biological Alarm Systems - BD Biosciences Immunocytometry Systems - Bertin Technologies - Biodefense - BioDETECT - BioSentinel Pharmaceuticals - BioTraces - BioVeris - Commonwealth Biotechnologies - Dycor Technologies - Environics - Evogen - General Dynamics Canada - GenPrime - Groton Biosystems - Haztech Systems - JMAR Technologies - New Horizons Diagnostics - Proengin - Response Biomedical - Tetracore For more information visit http://www.researchandmarkets.com/research/n5mnwh/global
GD: 137.61 (-0.54), A: 40.15 (+0.13), CPHD: 59.62 (+0.72)
Research and Markets: Global Bio-detection (1st, 2nd & 3rd Generation) Market 2014-2018 with Agilent Technologies, Cepheid, Roche Diagnostics & Smiths Group Dominating
Business Wire - Fri Jan 30, 1:22PM CST
Research and Markets (http://www.researchandmarkets.com/research/djxzmx/global) has announced the addition of the "Global Bio-detection Market 2014-2018" report to their offering.
A: 40.15 (+0.13), CPHD: 59.62 (+0.72)
Cepheid Posts Breakeven Earnings; System Placements High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 12:40PM CST
Cepheid (CPHD) reported 773 commercial placements during 2014, reflecting a strong North American performance, and 544 international placements, which far exceeded Cepheid's previous record of 383 international placements in 2013.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), EW: 134.23 (+1.89), CPHD: 59.62 (+0.72)
Cepheid's (CPHD) CEO John Bishop on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Jan 29, 10:02PM CST
CPHD: 59.62 (+0.72)
Cepheid reports 4Q loss
Automated Insights - Thu Jan 29, 5:37PM CST
SUNNYVALE, Calif. (AP) _ Cepheid (CPHD) on Thursday reported a loss of $23.8 million in its fourth quarter.
CPHD: 59.62 (+0.72)
CEPHEID (CPHD) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Jan 29, 3:55PM CST
CPHD: 59.62 (+0.72)
CEPHEID beats by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 3:13PM CST
CPHD: 59.62 (+0.72)
Cepheid Reports Fourth Quarter And Full Year 2014 Results
PR Newswire - Thu Jan 29, 3:05PM CST
Cepheid (Nasdaq: CPHD) today reported revenue for the fourth quarter of 2014 of $131.5 million. Net loss was $23.8 million, or $(0.34) per share, which compares to revenue of $113.3 million and net loss of $10.3 million, or $(0.15) per share, in the fourth quarter of 2013. 2014 fourth quarter net loss included a legal contingency charge of $20 million, or $(0.28) per share.
CPHD: 59.62 (+0.72)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 4:35PM CST
VR: 42.10 (+0.07), BXP: 141.08 (-1.58), EPAY: 27.07 (+0.64), CPSI: 53.11 (+0.26), GOOG: 549.01 (+6.08), PKI: 46.30 (-0.10), JDSU: 13.26 (+0.23), TFSL: 14.47 (+0.18), MITK: 3.38 (-0.02), NFG: 65.15 (+0.60), EFII: 40.59 (+0.94), BCR: 175.38 (+0.50), MCHP: 50.71 (+0.73), PMCS: 9.24 (+0.07), PFPT: 55.97 (+0.38), ABAX: 60.93 (+0.65), CPHD: 59.62 (+0.72), PFG: 51.60 (+0.50), QLGC: 14.48 (+0.48), UIS: 23.37 (+0.27), TUES: 19.41 (-0.01), COHR: 64.95 (+0.25), PCCC: 23.66 (+0.05), CTCT: 42.48 (+0.72), BIIB: 391.66 (-0.45), SFG: 67.49 (+0.21), IXYS: 11.92 (-0.07), SYNA: 78.91 (+0.87), HLIT: 7.90 (+0.01), INVN: 16.08 (+0.09), CB: 102.06 (+0.43), N: 101.72 (+3.38), ELX: 6.57 (+0.22), GIMO: 21.45 (+1.10), SWI: 50.55 (+0.79), V: 269.63 (-1.28), ELY: 8.61 (-0.05), GDOT: 15.54 (+0.34), FICO: 82.00 (+1.50), HBI: 119.12 (+1.27), ISBC: 11.70 (+0.07), NATI: 31.20 (+0.31), NEU: 469.55 (+0.43), AMZN: 381.83 (+4.66), EMN: 75.67 (+0.56), ALGN: 56.90 (-0.34), BRCM: 45.69 (+0.23), HA: 18.72 (-0.31), DECK: 77.08 (+0.61), LEG: 44.90 (+0.17), MTW: 21.86 (+0.34), RVBD: 20.85 (-0.03), AVNW: 1.19 (+0.08), RHI: 61.42 (+0.04), NGVC: 30.28 (+0.45), CORT: 3.15 (+0.01)
Comparing America's 3 Largest Scientific And Technical Instruments Companies
Joseph Cafariello - at Seeking Alpha - Tue Jan 27, 6:52AM CST
FLIR: 33.01 (-0.23), TRMB: 26.86 (-0.40), CPHD: 59.62 (+0.72)
Microbiology Testing/Clinical Microbiology Market by Product, Clinical Application & by Industry - Global Forecast to 2019
M2 - Fri Jan 16, 8:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/cl7fxt/microbiology) has announced the addition of the "Microbiology Testing/Clinical Microbiology Market by Product, Clinical Application & by Industry - Global Forecast to 2019" report to their offering. The global clinical microbiology market is expected to reach $12,411.36 million in 2019 at a CAGR of 13.03% between 2014 and 2019. Clinical microbiology consists of a wide array of techniques for the detection of infectious diseases. The respiratory diseases segment accounted for the largest application segment of the clinical microbiology market in 2014. According to the WHO, in 2012, there were about 450,000 new cases of multidrug-resistant tuberculosis (MDR-TB), and extensively drug-resistant tuberculosis (XDR-TB) was identified in 92 countries. Furthermore, the outbreak of new diseases such as Ebola is expected to increase the disease burden and the demand for clinical microbiology products. The microbiology market is segmented on the basis of applications into clinical, energy, environment, food, manufacturing, and pharmaceuticals. The food application segment is expected to grow at the highest CAGR between 2014 and 2019 however, the pharmaceuticals application segment accounted for the largest share of the microbiology market in 2014. On the basis of products, the clinical microbiology market is segmented into consumables and instruments. The clinical microbiology consumables market is further bifurcated into kits and reagents, whereas the instruments market is sub segmented into automated microbiology instruments, laboratory instruments, and microbiology analyzers. The microbiology analyzers are further categorized into mass spectrometers, microscopes, and molecular diagnostics instruments. The laboratory instruments are further categorized into anaerobic gas systems, automated gram strainers, automated petri dish fillers, autoclave sterilizers, bacterial colony counters, incubators, microbial air samplers, and other laboratory instruments. Clinical microbiology finds applications in a large number of disease diagnosis. The clinical microbiology market on the basis of applications are segmented into bloodstream infections, gastrointestinal diseases, periodontal diseases, respiratory diseases, sexually transmitted diseases, urinary tract infections, and other diseases. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Microbiology Market, By Applications 8 Clinical Microbiology Market, By Product 9 Clinical Microbiology Market, By Applications 10 Clinical Microbiology Market, By Geography 11 Competitive Landscape 12 Company Profiles - Abbott Laboratories, Inc. - Alere, Inc. - Becton, Dickinson and Company - Bio-Rad Laboratories, Inc. - Biom?rieux SA - Bruker Corporation - Cepheid - Danaher Corporation - F. Hoffmann-LA Roche Ltd. - Hologic, Inc. - Siemens AG For more information visit http://www.researchandmarkets.com/research/cl...crobiology
ABT: 46.09 (+0.87), CPHD: 59.62 (+0.72), DHR: 86.81 (+0.21), ALR: 43.40 (-0.40), HOLX: 30.46 (+0.21)
Cepheid CFO bids adieu
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 8:16AM CST
CPHD: 59.62 (+0.72)
PTC Names Andrew Miller Chief Financial Officer
Business Wire - Mon Jan 05, 7:12AM CST
PTC (Nasdaq
TC) today announced the appointment of Andrew Miller as Executive Vice President and Chief Financial Officer (CFO), effective February 5, 2015. An accomplished finance executive, Miller has more than 30 years of experience in the high technology and medical technology industries. CPHD: 59.62 (+0.72), PTC: 34.02 (+0.37), UNTD: 13.96 (-0.08)
Cepheid Announces CFO Change
PR Newswire - Mon Jan 05, 7:00AM CST
Cepheid (Nasdaq: CPHD) today announced that Andrew Miller, executive vice president and chief financial officer, will be leaving Cepheid to pursue an opportunity with PTC Inc., a Massachusetts-based technology solutions provider. Mr. Miller will continue to serve as Cepheid's CFO through February 3, 2015, directing Cepheid's financial operations and assisting with the upcoming transition.
CPHD: 59.62 (+0.72), PTC: 34.02 (+0.37)
Cepheid's (CPHD) Xpert HIV Test Wins CE-IVD Mark in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 1:40PM CST
Cepheid's (CPHD) HIV viral load test is the standard measurement which is used in the diagnosis of HIV positive patients and helps in administering antiretroviral therapy.
ETRM: 1.21 (+0.06), FLDM: 37.93 (-0.47), INGN: 33.53 (+2.32), CPHD: 59.62 (+0.72)
Cepheid and FIND Announce European Approval of Xpert HIV-1 Viral Load
PR Newswire - Mon Dec 29, 6:00AM CST
Cepheid (Nasdaq: CPHD) and the Foundation for Innovative New Diagnostics (FIND) today announced that Xpert® HIV-1 Viral Load, a quantitative test for measurement of the HIV-1 viral load in plasma, has a achieved CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices. The test runs on the Cepheid GeneXpert® System, the world's leading molecular diagnostic platform with over 7,500 systems deployed globally in both developed and emerging market countries.
CPHD: 59.62 (+0.72)
